The myokine oncostatin M has been shown to inhibit the proliferation of breast cancer cells, IL-6, IL-15, epinephrine and norepinephrine for the recruitment of NK cells and replacement of old neutrophils into new and more functional ones and limit induced inflammation by Macrophages M1 and increase in Macrophages M2 (anti-inflammatory).